Comparison of the solution structures of angiotensin I & II. Implication for structure-function relationship.

Conformational analysis of angiotensin I (AI) and II (AII) peptides has been performed through 2D 1H-NMR spectroscopy in dimethylsulfoxide and 2,2,2-trifluoroethanol/H2O. The solution structural models of AI and AII have been determined in dimethylsulfoxide using NOE distance and 3JHNHalpha coupling constants. Finally, the AI family of models resulting from restrained energy minimization (REM) refinement, exhibits pairwise rmsd values for the family ensemble 0.26 +/- 0.13 A, 1.05 +/- 0.23 A, for backbone and heavy atoms, respectively, and the distance penalty function is calculated at 0.075 +/- 0.006 A2. Comparable results have been afforded for AII ensemble (rmsd values 0.30 +/- 0.22 A, 1.38 +/- 0.48 A for backbone and heavy atoms, respectively; distance penalty function is 0.029 +/- 0.003 A2). The two peptides demonstrate similar N-terminal and different C-terminal conformation as a consequence of the presence/absence of the His9-Leu10 dipeptide, which plays an important role in the different biological function of the two peptides. Other conformational variations focused on the side-chain orientation of aromatic residues, which constitute a biologically relevant hydrophobic core and whose inter-residue contacts are strong in dimethylsulfoxide and are retained even in mixed organic-aqueous media. Detailed analysis of the peptide structural features attempts to elucidate the conformational role of the C-terminal dipeptide to the different binding affinity of AI and AII towards the AT1 receptor and sets the basis for understanding the factors that might govern free- or bound-depended AII structural differentiation.

[1]  M. Billeter,et al.  MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.

[2]  K. Barlos,et al.  Darstellung geschützter peptid-fragmente unter einsatz substituierter triphenylmethyl-harze , 1989 .

[3]  J. Bandekar,et al.  Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins. , 1986, Advances in protein chemistry.

[4]  P. Wright,et al.  Sensitivity improvement in proton-detected two-dimensional heteronuclear correlation NMR spectroscopy , 1991 .

[5]  K Wüthrich,et al.  Efficient analysis of protein 2D NMR spectra using the software packageEASY , 1991, Journal of biomolecular NMR.

[6]  H. Susi,et al.  Examination of the secondary structure of proteins by deconvolved FTIR spectra , 1986, Biopolymers.

[7]  P. Fromageot,et al.  Angiotensin II conformations. Infrared and raman studies. , 1972, European journal of biochemistry.

[8]  P. Schiller,et al.  The octapeptide angiotensin II adopts a well-defined structure in a phospholipid environment. , 1998, European journal of biochemistry.

[9]  E. Escher,et al.  Methylation in positions 1 and 7 of angiotensin II. A structure-activity relationship study. , 2009, International journal of peptide and protein research.

[10]  G. Moore,et al.  Importance of the N-terminal domain of the type I angiotension II antagonist [Sar1,Ile8]ANG II for receptor blockade. , 2009, International journal of peptide & protein research.

[11]  D. Regoli,et al.  The importance of residues 2 (arginine) and 6 (histidine) in high-affinity angiotensin II antagonists. , 1988, Journal of medicinal chemistry.

[12]  G R Marshall,et al.  Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem. , 1993, Biochemical and biophysical research communications.

[13]  W. Hsueh,et al.  Characterization of pure human renal renin. Evidence for a subunit structure. , 1987, The Journal of biological chemistry.

[14]  Richard R. Ernst,et al.  Multiple quantum filters for elucidating NMR coupling networks , 1982 .

[15]  K. Schaumburg,et al.  Conformational flexibility of angiotensin II. A carbon-13 spin-lattice relaxation study. , 1975, Biochemistry.

[16]  G. Han,et al.  9-Fluorenylmethoxycarbonyl amino-protecting group , 1972 .

[17]  T. Inagami,et al.  A review of mutagenesis studies of angiotensin II type 1 receptor, the three‐dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism , 1997, Journal of hypertension.

[18]  T Mavromoustakos,et al.  Role of the NH2-terminal domain of angiotensin II (ANG II) and [Sar1]angiotensin II on conformation and activity. NMR evidence for aromatic ring clustering and peptide backbone folding compared with [des-1,2,3]angiotensin II. , 1994, The Journal of biological chemistry.

[19]  E. C. Jorgensen,et al.  Angiotensin II analogs. 8. The use of free radical containing peptides to indicate the conformation of the carboxyl terminal region of angiotensin II. , 1971, Journal of the American Chemical Society.

[20]  Y. Shin,et al.  Conformational study of angiotensin II. , 1998, Biopolymers.

[21]  G. Moore,et al.  I. 1H-NMR studies of [Sar1]angiotensin II conformation by nuclear Overhauser effect spectroscopy in the rotating frame (ROESY): Clustering of the aromatic rings in dimethylsulfoxide , 1990, Peptides.

[22]  C. Ferrario,et al.  Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. , 1998, Hypertension.

[23]  G. Némethy,et al.  Proposed models for angiotensin II in aqueous solution and conclusions about receptor topography. , 1972, Nature: New biology.

[24]  A. Rauk,et al.  Mechanistic consequences of charge transfer systems in serine proteases and angiotensin: semiempirical computations. , 1987, Biochemical and biophysical research communications.

[25]  G. Moore,et al.  Angiotensin as a model for hormone — receptor interactions , 1985, Bioscience reports.

[26]  Ad Bax,et al.  MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy , 1985 .

[27]  T Mavromoustakos,et al.  An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations. , 1999, Journal of medicinal chemistry.

[28]  S. Han,et al.  Residues Val254, His256, and Phe259 of the angiotensin II AT1 receptor are not involved in ligand binding but participate in signal transduction. , 1998, Molecular endocrinology.

[29]  G. Moore,et al.  Synthesis and biological activities of analogues of angiotensins II and III containing O-methyltyrosine and D-tryptophan. , 1985, Journal of medicinal chemistry.

[30]  M. Juy,et al.  The key role of residue 5 in angiotensin II , 1983, Biopolymers.

[31]  L. Craig,et al.  Evidence for the presence of hydrogen-bonded secondary structure in angiotensin II in aqueous solution. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Karnik,et al.  The Docking of Arg2 of Angiotensin II with Asp281 of AT1 Receptor Is Essential for Full Agonism (*) , 1995, The Journal of Biological Chemistry.

[33]  E. Escher,et al.  Angiotensin II Analogues with Sulphur-containing Side-chains in Position 5 , 2000, Arzneimittelforschung.

[34]  I. Gerothanassis,et al.  17O NMR and FT‐IR study of the ionization state of peptides in aprotic solvents Application to Leu‐enkephalin , 1992, FEBS letters.

[35]  K. Wüthrich,et al.  The relevance of J cross-peaks in two-dimensional NOE experiments of macromolecules , 1982 .

[36]  K. Wüthrich,et al.  Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins. , 1983, Biochemical and biophysical research communications.

[37]  E. C. Jorgensen,et al.  Angiotensin II analogs. IX. Conformational studies of angiotensin II by proton magnetic resonance. , 1971, Journal of the American Chemical Society.

[38]  I. Reid.  The renin-angiotensin system and body function. , 1985, Archives of internal medicine.

[39]  K. Lintner,et al.  Conformation of the central sequence of angiotensin II and analogs , 1983, Biopolymers.

[40]  M. Liakopoulou-Kyriakides,et al.  s-Cis and s-trans isomerism of the His-Pro peptide bond in angiotensin and thyroliberin analogues. , 1979, Biochemistry.

[41]  H. Scheraga,et al.  Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of AII and cyclic analogs. , 2009, International journal of peptide and protein research.

[42]  K. Wüthrich.  NMR of proteins and nucleic acids , 1988 .

[43]  R. Leduc,et al.  Photolabeling identifies position 172 of the human AT(1) receptor as a ligand contact point: receptor-bound angiotensin II adopts an extended structure. , 2000, Biochemistry.

[44]  E. Ralston,et al.  Theoretical conformational analysis of Asn1, Val5 angiotensin II , 1977, Biopolymers.

[45]  K. Wüthrich,et al.  Torsion angle dynamics for NMR structure calculation with the new program DYANA. , 1997, Journal of molecular biology.

[46]  K Wüthrich,et al.  Efficient computation of three-dimensional protein structures in solution from nuclear magnetic resonance data using the program DIANA and the supporting programs CALIBA, HABAS and GLOMSA. , 1991, Journal of molecular biology.

[47]  D. Regoli,et al.  Pharmacology of angiotensin. , 1974, Pharmacological reviews.

[48]  G. Marshall,et al.  Conformational analysis of two cyclic analogs of angiotensin: implications for the biologically active conformation. , 1994, Biochemistry.

[49]  G. Moore.  Kinetics of acetylation-deacetylation of angiotensin II. Intramolecular interactions of the tyrosine and histidine side-chains. , 2009, International journal of peptide and protein research.

[50]  G. Marshall,et al.  Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications. , 1996, Journal of medicinal chemistry.

[51]  Yoshihisa Inoue,et al.  Mutagenesis and the Molecular Modeling of the Rat Angiotensin II Receptor (AT1) (*) , 1995, The Journal of Biological Chemistry.

[52]  Richard R. Ernst,et al.  Investigation of exchange processes by two‐dimensional NMR spectroscopy , 1979 .

[53]  S. Karnik,et al.  Interaction of Phe8 of Angiotensin II with Lys199 and His256 of AT1 Receptor in Agonist Activation (*) , 1995, The Journal of Biological Chemistry.

[54]  G. Moore,et al.  A new approach to angiotensin antagonists: methylation of the tyrosine hydroxyl in angiotensin II. , 1984, Life sciences.

[55]  G. Marshall,et al.  The utility of side‐chain cyclization in determining the receptor‐bound conformation of peptides: Cyclic tripeptides and angiotensin II , 1992, Biopolymers.

[56]  A T Brünger,et al.  Three-dimensional structure of an angiotensin II-Fab complex at 3 A: hormone recognition by an anti-idiotypic antibody. , 1992, Science.

[57]  T Mavromoustakos,et al.  The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II. , 2000, Bioorganic & medicinal chemistry.

[58]  Pierson Me,et al.  Analysis of the active conformation of angiotensin II: a comparison of AII and non-peptide AII antagonists. , 1992 .

[59]  K Wüthrich,et al.  Pseudo-structures for the 20 common amino acids for use in studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear magnetic resonance. , 1983, Journal of molecular biology.